Glenmark receives approval for Deferasirox Tablets

Glenmark Pharmaceuticals Inc. received ANDA approval for Deferasirox Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg.

The drug maker received the final approval from Untied States Food & Drug Administration (USFDA). Deferasirox Tablets for Oral Suspension, 125 mg, 250 mg, and 500 mg is a generic version of Exjade Tablets for Oral Suspension, 125 mg, 250 mg, and 500 mg of Novartis Pharmaceuticals Corporation. The Exjade Tablets for Oral Suspension, 125 mg, 250 mg, and 500 mg achieved annual sales of approximately US$106.4 million, according to IQVIAsales data for 12 months ended November 2019.

Glenmark Pharmaceuticals Ltd. (GPL) is a global innovative pharmaceutical company, with operations across the world. It primarily focuses in the areas of oncology, respiratory and dermatology. It has a significant presence in generic drugs market and has improved lives of millions of patients by offering safe and affordable medication for a period of time. Additional to the new filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

On Tuesday, the stock of the company closed at Rs 343.15, up by 1.03 per cent or Rs 3.50 per share. The intraday high is Rs 349.20 and intraday low is Rs 339. The 52-week high is Rs 674.75 and 52-week low is Rs 267.30 on the BSE.